Stocks in Play - 10th February 2026

Today in Focus: EVMN, NKTR

Sources & Services I Use in my Trading:

• Finviz - Scanning, Short Interest, Float, Fundamentals

• Benzinga Pro - News + Squawk

• Tradingview - Charting & Scanning

• BiopharmaIQ - FDA Calendars & Upcoming Biotech Catalysts

• Koyfin - Fundamental Data

• Tradersync - Trade Journal

Situational Awareness

Market Condition: QQQ Below all major Moving Averages. Bounce Friday, Continuation Monday. DIA and RSP at All Time Highs. SPY and IWM also strong.

Commentary: Solid continuation yesterday. Good price action, catalysts following through. Indices looking good except for QQQ which is testing underside of MAs today. The QQQ weakness is to be expected with the SaaSpocalyse that’s been occurring recently. We’re on day 3 of the bounce today so I am more cautious and don’t be surprised to see some whipsaw action punishing those who are late to the party.

Upcoming Earnings:
After Hours: MAT, HOOD, ALAB, AEIS, JHX, LSCC, RRR, UFCS, DIOD, ELMD, OI, VREX
Before Open: VRT, GFS, LAD, NI, SITE, SN, SOLS, SW, FLNG

Trade Updates:

Current Positions: INTC, STM, WULF, VG, INNV, ROIV, MPC, PLBY, GLW

Stopped on MAXN, Stopped on INTC but reentered. Trimmed some names into strength GLW, MPC.

Updated delayed reaction watchlist.

In Play

NKTR/EVMN:  Two Atopic Dermatitis Catalyst Announcements Today

Key Metrics NKTR: Industry Group: Biotechnology, Market Cap: 857.80M, Float: 20.04M, Short Interest: 16.29%, Days to Cover: 4.23, Sales Y/Y TTM: -32.79%, EPS Y/Y TTM: 36.87%, Earnings: Nov 06 AMC, Exchange: NASDAQ

Key Metrics EVMN: Industry Group: Biotechnology, Market Cap: 869.43M, Float: 17.75M, Short Interest: 10.73%, Days to Cover: 8.39, Sales Y/Y TTM: -, EPS Y/Y TTM: -, Earnings: Dec 11 AMC, Exchange: NASDAQ

Catalyst: Evommune announced positive Phase 2a proof-of-concept results for EVO301, a novel IL-18 inhibitor fusion protein, in moderate-to-severe atopic dermatitis. Nektar reported 36-week maintenance data from its 393-patient Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin (REZPEG), a novel regulatory T-cell (Treg) biologic, in moderate-to-severe atopic dermatitis.

Interesting one here. Two separate catalysts regarding the same illness. My understanding is that NKTR is far superior data/quality however EVMN is a recent IPO and meaningful Short Interest. I traded NKTR last year the chart is on the back end but can still work. I’m looking at both of these today.

Delayed Reaction/Continuation Watchlist:

Monitoring:

• GME

• ENPH

• INTC

• EGHT

Delayed Reaction Watchlist (TradingView Link)

Like what you're reading? Support this work via ☕ Ko-Fi.

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}